A federal judge ordered Guardant Health to pay over $245 million to TwinStrand Biosciences and the University of Washington. This judgment follows a jury verdict for infringing patented DNA sequencing technology. Guardant Health will pay an upfront amount and an ongoing royalty until March 2033. The company announced it will appeal the final judgment and is confident in its position.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.